文献速递肝胆胰外科围术期管理与 ERAS

后腹腔镜肾上腺切除术在成本与利润方面可能优于腹腔镜经腹腔肾上腺切除术:一项回顾性配对队列分析

Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis.
PubMed 文献 · Surg Endosc · 2023-09-01

本研究基于内分泌外科登记数据,回顾性配对比较2019至2022年间接受后腹腔镜肾上腺切除术(RPA)与腹腔镜经腹腔肾上腺切除术(LTA)各43例患者的围手术期变量、治疗成本、收入与利润。RPA的治疗成本低于LTA(5789.99美元 vs 6617.75美元,P=0.043),利润高于LTA(1235.59美元 vs 653.33美元,P=0.027)。结论认为RPA在围手术期发病率、住院时间及成本效益方面可能优于LTA。

要点

  • 配对后RPA与LTA各43例,患者特征具有可比性。
  • RPA治疗成本5789.99美元低于LTA的6617.75美元(P=0.043)。
  • RPA利润1235.59美元高于LTA的653.33美元(P=0.027)。

核心结论

  • RPA在围手术期发病率、住院时间及财务成本效益方面似乎优于LTA。

研究设计与样本

  • 单中心回顾性观察性队列研究,基于内分泌外科登记数据,纳入2019至2022年手术患者,配对后RPA与LTA各43例。

主要发现

  • RPA治疗成本为5789.99美元,LTA为6617.75美元,P=0.043。
  • RPA利润为1235.59美元,LTA为653.33美元,P=0.027。
  • 住院时间和合并症显著影响治疗成本及总体利润。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A direct comparison of the cost-benefit analysis of retroperitoneoscopic adrenalectomy (RPA) versus the minimally invasive transperitoneal access (LTA) approach is currently lacking. We hypothesized that RPA is more cost effective than LTA; promising significant savings for the healthcare system in an era of ever more limited resources. METHODS: We performed a monocentric retrospective observational cohort study based on data from our Endocrine Surgery Registry. Patients who were operated upon between 2019 and 2022 were included. After pair-matching, both cohorts (RPA vs. LTA) were compared for perioperative variables and treatment costs (process cost calculation), revenue and profit. RESULTS: Two homogenous cohorts of 43 patients each (RPA vs. LTA) were identified following matching. Patient characteristics between the cohorts were comparable. In terms of both treatment-associated costs and profit, the RPA procedure was superior to LTA (costs: US$5789.99 for RPA vs. US$6617.75 for LTA, P = 0.043; profit: US$1235.59 for RPA vs. US$653.33 for LTA, P = 0.027). The duration of inpatient treatment and comorbidities significantly influenced the cost of treatment and the overall profit. CONCLUSIONS: RPA appears not only to offer benefits over LTA in terms of perioperative morbidity and length of hospital stay, but also has a superior financial cost/benefit profile.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Fischer A, Schöffski O, Nießen A, et al. Retroperitoneoscopic adrenalectomy may be superior to laparoscopic transperitoneal adrenalectomy in terms of costs and profit: a retrospective pair-matched cohort analysis. Surg Endosc. 2023. PMID: 37658201. doi:10.1007/s00464-023-10395-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。